Regulatory
ViiV Healthcare’s Rukobia (fostemsavir) Receives Marketing Authorization for the Treatment
Shots: The MAA is based on P-III BRIGHTE study assessing Rukobia (600mg, bid) + OBT vs PBO in 371 HTE adults living with multidrug-resistant HIV. Participants were enrolled in either […]readmore